A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Rilvegostomig
DRUG: Ramucirumab
DRUG: Dato-DXd

Sponsor

AstraZeneca

Collaborators

[object Object]